Menopause specialists and physicians across Canada have expressed concern following Pfizer’s decision to discontinue the supply of Premarin vaginal cream and oral estrogen tablets in the Canadian market, while continuing to distribute these products in the United States. The move was announced publicly last week, with existing inventories expected to last into mid-2027.
Premarin, an estrogen therapy first approved in Canada in 1941, is commonly prescribed to alleviate menopause symptoms such as vaginal dryness, atrophic vaginitis, and dyspareunia. The active ingredient is produced by Pfizer at a facility in Brandon, Manitoba, derived from the urine of pregnant mares in the provinces of Manitoba and Saskatchewan.
Pfizer Canada informed Health Canada on November 3 of its intent to cease supplying Premarin products domestically, according to information in a federal drug-shortage database. While Premarin cream is being removed from the Canadian market immediately, the oral tablets will remain available until the existing stock is depleted, possibly until June 2027. Pfizer cited the products as “commercially unsustainable” in Canada, referencing factors such as manufacturing costs, pricing, reimbursement policies, and long-term supply viability. The Premarin cream has experienced recurring shortages in Canada since early 2025.
Demand for menopause hormone therapy is rising in both Canada and the U.S., although regulatory approaches differ. The U.S. Food and Drug Administration removed certain safety warnings for these therapies last November, contributing to increased uptake. Health Canada, however, has not yet altered similar cautionary guidelines. A report from Manulife Canada in September documented a 228 percent increase over five years in hormone-replacement therapy claims among women aged 45 to 54 and older.
Canadian clinicians warn that the discontinuation may have significant clinical implications. Obstetrician-gynecologist Jen Gunter highlighted concerns about access to hormone therapies in general, urging public engagement on the issue. Family physician Rithvika Ramesh, based in Toronto, noted that Premarin cream is the sole vaginal estrogen formulation covered by the Ontario Drug Benefit program, a provincial funding plan that supports medication costs for eligible individuals. She emphasized that the cream is a key treatment not only for genitourinary menopausal symptoms but also for preventing recurrent urinary tract infections (UTIs), which can escalate to serious complications such as sepsis in older adults.
Provincial health authorities have indicated that alternative vaginal estrogen products, including rings, tablets, and inserts identified by the Canadian Menopause Society, remain accessible through public drug formularies. The Canadian Pharmacists Association has also developed guidance to help healthcare providers manage supply disruptions linked to the discontinuation.
Patients who depend on Premarin may face increased out-of-pocket expenses or be forced to shift to alternatives that might not address their symptoms as effectively, health professionals warn. Gunter has called on the federal government to investigate the reasons behind Pfizer’s decision and consider measures to protect access to essential menopause treatments. A spokesperson for Health Minister Marjorie Michel confirmed that Health Canada is reviewing the impact of Premarin’s withdrawal on the availability of hormone therapies and will take steps to mitigate any shortages.
